NYSE:ABBV

AbbVie Inc.

United StatesConsumerPharmaceutical PreparationsNYSE

288.24

USD · Close 5 Nov 2026

Intrinsic value vs last close

Model estimate

Close above intrinsic value

−30.5%Intrinsic value vs last close

−50%At last close+100%+500%

Last close (USD): 288.24
Intrinsic value (USD): 200.24

Intrinsic value = sector model's value (no adjustment)

Earnings-capitalised value

34.10−88.2%vs last close

Cost of equity 11.0% · price volatility 25.4%

Last year's earnings per share, capitalised at a cost of equity that rises with this share's own price swings, growing at the sector's long-run rate.

This is a different figure from the intrinsic value above. The intrinsic value is what the sector model says the business is worth. On Vietnamese stocks this figure has ranked future returns best in our track record; this market has no track record here yet.

Model reliability: Low; Model fitInput stabilityRisk checks; High requires the model’s diagnostic criteria to be met.
Probability of outperforming peers: Not assessed; A separate peer-outperformance probability is unavailable for this valuation.

Assessed 5 Nov 2026Not updated with daily prices

These assessments address different questions. Neither establishes that the displayed valuation is correct or guarantees a future return.

Published filingsValued 5 Nov 2026Anchored to close on 5 Nov 2026The gap is recalculated when the close changes; the value updates weekly.

Valuation Breakdown

Pharmaceutical Preparations→Consumer

Classified as consumer from the industry its market data reports: “Pharmaceutical Preparations”.

ModelFCF-Based DCF

Intrinsic = 70% x DCF Value + 30% x (Fair P/E x EPS)

A Discounted Cash Flow model built on Free Cash Flow (FCF), the cash a business generates after operating expenses and capital expenditures. Future FCF is projected for 10 years with gradually decaying growth, then discounted to today's value using WACC. The DCF value is blended 70/30 with a value from the company's own historical P/E.

Technical details

Why this model

Consumer staples/retail generate steady, predictable free cash flows, making them ideal for DCF. The time value of money principle means a dollar today is worth more than a dollar tomorrow. DCF captures this by discounting future cash flows at a rate reflecting the investment's risk (WACC).

How it works

Takes 3-year median FCF as the base. Estimates growth via ROIC x reinvestment rate (Damodaran framework), falling back to historical revenue growth. Projects 10 years with decay toward the sector's long-run growth rate. Discounts at CAPM-derived WACC. Blends 70% of the DCF value with 30% of a P/E value: the company's 5-year median P/E, held between 5x and 25x, times EPS.

Best for

Stable consumer businesses (food, beverage, retail, healthcare) with predictable, positive free cash flows.

Weighted Avg Cost of Capital

Risk-Free (Rf)

4.94%

Betasector default

0.910

ERP

4.20%

CRP

0.22%

Cost of Equity (Ke)

8.98%

E/(D+E)

16.67%

Kd(1-t)

3.52%

D/(D+E)

83.33%

WACC

8.00%

Growth Estimate

historical blend4.00%

Growth decays 10%/yr toward terminal

Model Inputs

Base FCF→20.09B

Projection years→10

Valuation

We compare the sector model's value with the last close. This market has no track record here yet, so the value is shown as the model gives it.

Last close (USD)→288.24

Intrinsic value vs last close→−30.5%

Intrinsic value = sector model's value (no adjustment)

Intrinsic value (USD)

200.24

What feeds each step— click a source to highlight it in the statements

Discount rate (WACC)8.00%

Growth rate4.00%growth method: historical blend

Base cash flow20.1Bone off strip ratio: 0

DCF Sensitivity

Values from the standalone DCF scenarios below. These scenarios leave out the other parts of a blended model and do not reproduce the headline value.

WACC \ Growth	1.0%	2.5%	4.0%	5.5%	7.0%
6.0%	539.06	547.59	556.11	572.60	606.39
7.0%	347.79	353.47	359.15	370.08	392.25
8.0%	252.15	256.41	260.67	268.82	285.19
9.0%	194.77	198.17	201.58	208.06	220.96
10.0%	156.51	159.35	162.19	167.56	178.14

Above market priceBelow market priceCurrent estimate

NYSE:ABBV among Consumer

Every valued stock in the sector on this market, NYSE:ABBV marked: model value vs close across, market value up, model reliability into the board

Each bead is one valued stock in the sector; the amber bead with its stem is NYSE:ABBV. Drag to turn; open another stock from its bead.

Feeds valuation:Cost of capitalGrowthModel inputsFinal calculation

Line item	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Cash and cash equivalentsNet debt bridge	·	5,229	5,524	12,814	9,201	9,746	8,449	39,924	7,289	9,303	5,100	8,399	8,348	9,595	5,901	27	10
Short-term investmentsNet debt bridge	·	28	31	2	28	84	30	0.00	772	486	1,323	8	26	300	2,075	·	·
Inventories, Net	·	4,951	4,181	4,099	3,579	3,128	3,310	1,813	1,605	1,605	1,444	1,719	1,124	1,150	1,091	·	·
Fixed assets	·	5,628	5,134	4,989	4,935	5,110	5,248	2,962	2,883	2,803	2,604	2,565	2,485	2,298	2,247	·	·
TOTAL ASSETS	·	133,960	135,161	134,711	138,805	146,529	150,565	89,115	59,352	70,786	66,099	53,050	27,547	29,198	27,008	·	·
Short-term borrowingsDiscount rate (WACC) +1	·	2,499	0.00	0.00	1	14	34	0.00	3,699	400	377	406	425	413	1,020	·	·
Long-term borrowingsDiscount rate (WACC) +1	·	58,941	60,340	52,194	59,135	64,189	77,554	62,975	35,002	30,953	36,440	29,240	10,565	14,292	14,630	·	·
OWNER'S EQUITYDiscount rate (WACC)	·	−3,228	3,364	10,397	17,287	15,436	13,097	−8,172	−8,446	5,097	4,636	3,945	1,742	4,492	−350	·	·
MINORITY INTERESTSNet debt bridge	·	42	39	37	33	28	21	0.00	·	·	·	·	·	·	·	·	·

Earnings Quality

Fiscal year 2025

Good

Accrual QualityLow accruals vs reported earnings

100

Cash ConversionOperating cash flow vs net income

100

Margin StabilityConsistency of profit margins

Revenue QualityConsistency of revenue growth

Quantitative Scores

F-Score

6/9

Neutral

Sharpe

1.02

Above 1

Composite

30 to 49

Piotroski F-Score Breakdown

✓Net Income > 0

✓Operating CF > 0

✗ROA Rising

✓OCF > Net Income

✓Lower Leverage

✗Better Liquidity

✓No Dilution

✗Margin Up

✓Turnover Up

Price Risk

Momentum

+25.7%

Volatility

22.7%

Max Drawdown

−16.5%

Key Ratios

Fiscal year 2025

124.31P/E

P/B: —
P/S: 8.52
EPS: 2.37
BVPS: −1.82
Net Margin: 6.9%
D/E: —
Rev Growth: +8.6%
EV/EBITDA: 36.46
Div Yield: —

Company Overview

Shares outstanding: 1,768M
Industry: Pharmaceutical Preparations

Computed 05/11/2026

Intrinsic value vs last close

Earnings-capitalised value

Valuation Breakdown

DCF Sensitivity

NYSE:ABBV among Consumer

Financial Statements

Earnings Quality

Quantitative Scores

Key Ratios

Company Overview

NYSE:ABBV among Consumer